Daily Care News from October 24, 2018
advertisement
- Decreasing Cumulative Incidence of End-Stage Renal Disease in Young Patients With Type 1 Diabetes in Sweden: A 38-Year Prospective Nationwide Study.
- The physiological factors influencing diabetes control in children using insulin pumps from diabetes type 1 diagnosis.
- Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Free full text available in PDF format.
- Continuous Glucose Monitoring Use and Glucose Variability in Pre-school Children with Type 1 Diabetes.
- The Association between glycemic variability in continuous glucose monitoring and cardiovascular autonomic neuropathy independent of mean glucose in adults with type 1 diabetes: Importance of level 2 hypoglycemia.
- Differences Between Flash Glucose Monitor and Fingerprick Measurements. Free full text available in HTML and PDF formats.
- Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring.
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
- Factors That Affect Quality of Life in Young Adults With Type 1 Diabetes.
- Executive function and somatic problems in adolescents with above target glycemic control.
- Executive Function Predicting Longitudinal Change in Type 1 Diabetes Management During the Transition to Emerging Adulthood.
- Poor Metabolic Control in Children and Adolescents With Type 1 Diabetes and Psychiatric Comorbidity.
- The peripheral atherosclerotic profile in patients with type 1 diabetes mellitus warrants a thorough vascular assessment of asymptomatic patients.
- Childhood Diabetes Lowers Lifespan by 18 Years.
- SGLT2 Use For Treating Type 1 Diabetes – What You Need to Know.
- EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk. (Free Medscape membership required)
